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Vitiligo is an acquired, idiopathic disease char-acterized by depigmented macules and patches,
with total absence of functional melanocytes within
the areas of affected skin. This is a condition that
occurs worldwide, with an estimated prevalence of
1% but with reported rates as high as 4% in some
countries. Although spontaneous remission may
occur, given that the condition is associated with
significant emotional distress for patients, treatment
of the condition is indicated.1
Treatment of vitiligo is generally divided into two
categories—therapies aimed at repigmentation of
affected skin and therapies aimed at depigmentation
of unaffected skin for blending of overall skin tones.
Depigmentation is often preferred in extensive cases
in which vitiligo affects more than 50% of the total
body surface area. Depigmentation may be achieved
through the use of topical 20% monobenzyl ether of
hydroquinone (MBEH), MBEH in combination with
tretinoin, 4-methoxyphenol, 88% phenol solution,
cryotherapy, or laser therapy.1 The 694-nm quality-
switched (QS) ruby and the 755-nm QS alexandrite
lasers have been shown to be effective for depig-
mentation of recurrent or resistant relative hyper-
pigmentation in patients with vitiligo.1,2 In this case,
the 532-nm QS frequency-doubled neodymium-
doped yttrium aluminum garnet (Nd:YAG) laser
was used successfully to treat areas of recalcitrant
pigmentation and recurrent pigmentation after full-
body chemical depigmentation therapy for vitiligo.
Case Report
A 23-year-old woman of Middle Eastern descent
with baseline Fitzpatrick type III skin presented to
our clinic for treatment of patchy areas of relative
hyperpigmentation involving her face, arms, trunk,
and legs that had been present for longer than
1 year. She had a history of extensive vitiligo
beginning at the age of 8 that failed to repigment
after multiple treatment attempts. She underwent
total body chemical depigmentation with 20%
MBEH at the age of 12, with generally excellent
results aside from areas of recalcitrant pigmentation
on the extremities. The patient continued to use
topical MBEH therapy intermittently for the next
4 years to treat the persistent pigmentation and
areas of sun-induced repigmentation. Eventually, she
began to note areas of repigmentation that were
resistant to further attempts at chemical depigmen-
tation. She presented to our clinic for a discussion of
other therapeutic options. Examination at that time
revealed Fitzpatrick skin type I with blotchy, mac-
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ular, light brown relative hyperpigmentation scat-
tered over the forehead, temples, cheeks, legs, and
arms (Figure 1).
After confirmation of efficacy on a test spot, the
patient was treated serially with nonoverlapping
pulses of a 532-nm QS Nd:YAG laser with a 3- to
4-mm spot size and a fluence of 1.1 to 1.8 J/cm2
followed by application of petrolatum several times
daily for approximately 7 days. Twice-daily appli-
cations of 4% hydroquinone cream were begun
approximately 1 week after treatment, and she also
began strict and continuous daily sunscreen use peri-
operatively except during the first week after each
treatment because of concerns about potential skin
irritation. This overall treatment protocol produced
excellent results (Figure 2). Aside from the expected
purpura secondary to the laser therapy, she experi-
enced no side effects from the procedure during any
of her treatment sessions. Each treated site generally
responded completely after one treatment session,
but any residual relative hyperpigmentation was
treated every 6 to 8 weeks until it resolved.
Over the past 7 years, the patient has been treated
intermittently on an as-needed basis, typically
requiring treatment of new breakthrough repig-
mentation no more than once per year. Treated sites
have included the face, trunk, and all extremities. In
most cases, treated sites have not repigmented over a
period of several years.
Discussion
Treatment of extensive vitiligo by removing residual
pigmentation can be an effective way to improve
cosmesis in patients who fail to respond to therapies
aimed at repigmentation of affected skin or in
patients with more than 50% total body surface area
involvement. One of the most widely used means of
achieving depigmentation is with twice-daily appli-
cation of 20% MBEH.1 This treatment must gener-
Figure 1. Blotchy macular hyperpigmentation of the
patient’s face secondary to recurrent pigmentation after
treatment with topical 20% monobenzyl ether of hydroqui-
none.
Figure 2. Clearance of hyperpigmentation several weeks
after a single quality-switched frequency-doubled neodym-




ally be continued for many months and has a
relatively high failure rate. One retrospective review
of 18 patients showed that complete depigmentation
was achieved in only eight. The degree of depig-
mentation achieved correlated with duration of use,
sometimes requiring use for 10 months or more to
achieve complete depigmentation.3 The preparation
may be difficult to tolerate because it causes ocular
and cutaneous chemical irritation.1 Additionally,
areas of skin may repigment at a later date, leaving
the patient cosmetically disfigured.3
Options such as cryotherapy and laser therapy that
target melanocytes for destruction have been shown
to be effective for removal of residual pigmentation
not responsive to additional chemical depigmenta-
tion or for patients unable to tolerate the side effects
of chemical depigmentation.1,2 Additionally,
although the Koebner phenomenon may be more
common in progressive vitiligo than stable vitiligo,4
treatments such as laser therapy may initiate a
Koebner response in the affected areas, making them
even more amenable to laser treatment than other
pigmented lesions.2
The most widely reported lasers used for this
purpose are the QS ruby (694 nm) and alexandrite
(755 nm) lasers.1,2 Although the 532-nm QS Nd-
YAG laser has been shown to be effective for
treatment of various pigmented lesions,5 to our
knowledge, there are no reports of it being used to
treat residual or recurrent relative hyperpigmenta-
tion in vitiligo.
We present this case to illustrate the efficacy of the
532-nm QS Nd:YAG laser in the treatment of
pigmentary disturbances in vitiligo, providing
another therapeutic option for this distressing dis-
order. Our patient tolerated laser treatment well,
with no side effects. The patient has intermittently
required additional treatment of newly pigmented
areas but has maintained long-lasting results with
excellent cosmesis after this therapy.
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